Neonatal Agenesis of Corpus Callosum in a Pregnant Lady with Multiple Endocrine Neoplasia Type I
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
(12) Patent Application Publication (10) Pub. No.: US 2007/0254315 A1 Cox Et Al
US 20070254315A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0254315 A1 Cox et al. (43) Pub. Date: Nov. 1, 2007 (54) SCREENING FOR NEUROTOXIC AMINO (60) Provisional application No. 60/494.686, filed on Aug. ACID ASSOCATED WITH NEUROLOGICAL 12, 2003. DSORDERS Publication Classification (75) Inventors: Paul A. Cox, Provo, UT (US); Sandra A. Banack, Fullerton, CA (US); Susan (51) Int. Cl. J. Murch, Cambridge (CA) GOIN 33/566 (2006.01) GOIN 33/567 (2006.01) Correspondence Address: (52) U.S. Cl. ............................................................ 435/721 PILLSBURY WINTHROP SHAW PITTMAN LLP (57) ABSTRACT ATTENTION: DOCKETING DEPARTMENT Methods for screening for neurological disorders are dis P.O BOX 105OO closed. Specifically, methods are disclosed for screening for McLean, VA 22102 (US) neurological disorders in a Subject by analyzing a tissue sample obtained from the subject for the presence of (73) Assignee: THE INSTITUTE FOR ETHNO elevated levels of neurotoxic amino acids or neurotoxic MEDICINE, Provo, UT derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neu (21) Appl. No.: 11/760,668 rological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a Subject, by deter (22) Filed: Jun. 8, 2007 mining the levels of B-N-methylamino-L-alanine (BMAA) Related U.S. Application Data in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neuro (63) Continuation of application No. 10/731,411, filed on logical disorders are disclosed. Methods for inhibiting, treat Dec. 8, 2003, now Pat. No. 7,256,002. -
Practitioners' Section
407 408 GENETICS OF MENTAL RETARDATION [2] [4] PRACTITIONERS’ SECTION epiphenomena. A specific cause for mental a group heritability of 0.49. The aetiology of retardation can be identified in approximately idiopathic mental retardation is usually 80% of people with SMR (IQ<50) and 50% of explained in terms of the ‘polygenic GENETICS OF MENTAL RETARDATION people with MMR (IQ 50–70). multifactorial model.’ The difficulty is that there A. S. AHUJA, ANITA THAPAR, M. J. OWEN are too few studies to provide sufficiently In this article, we will begin by considering precise estimates of the likely role of genes ABSTRACT what is known about the genetics of idiopathic and environment in determining idiopathic mental retardation and then move onto discuss mental retardation. Given the dearth of Mental retardation can follow any of the biological, environmental and psychological events that are capable of producing deficits in cognitive functions. specific genetic causes of mental retardation. published literature we are reliant on Recent advances in molecular genetic techniques have enabled us to understand attempting to draw conclusions from family and more about the molecular basis of several genetic syndromes associated with mental Search methodology twin studies, most of which are very old and retardation. In contrast, where there is no discrete cause, the interplay of genetic Electronic searching was done and the which report widely varying recurrence risks.[5] and environmental influences remains poorly understood. This article presents a relevant studies were identified by searching Recent studies of MMR have shown high rates critical review of literature on genetics of mental retardation. -
ICARE: Interagency Collaborative to Advance Research in Epilepsy 2014 Member Reports
ICARE: Interagency Collaborative to Advance Research in Epilepsy 2014 Member Reports Table of Contents National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke (NINDS) ............................................................... 2 National Heart, Lung, and Blood Institute (NHLBI) ..................................................................................... 4 National Institute on Alcohol Abuse and Alcoholism (NIAAA) ................................................................... 7 The National Institute of Biomedical Imaging and Bioengineering (NIBIB)................................................ 9 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) .............. 10 National Institute on Drug Abuse (NIDA) ................................................................................................... 12 Other Federal Participants Centers for Disease Control and Prevention (CDC) CDC Epilepsy Program .............................................................................................................................. 13 National Center on Birth Defects and Developmental Disabilities (NCBDDD) ....................................... 17 Office of the Assistant Secretary for Health, U.S. Department of Health and Human Services ................. 20 Department of Veterans Affairs (VA) Epilepsy Centers of Excellence (ECoE) ......................................... 22 Nongovernmental Organizations American Epilepsy Society (AES) .............................................................................................................. -
Genetic Disorder
Genetic disorder Single gene disorder Prevalence of some single gene disorders[citation needed] A single gene disorder is the result of a single mutated gene. Disorder Prevalence (approximate) There are estimated to be over 4000 human diseases caused Autosomal dominant by single gene defects. Single gene disorders can be passed Familial hypercholesterolemia 1 in 500 on to subsequent generations in several ways. Genomic Polycystic kidney disease 1 in 1250 imprinting and uniparental disomy, however, may affect Hereditary spherocytosis 1 in 5,000 inheritance patterns. The divisions between recessive [2] Marfan syndrome 1 in 4,000 and dominant types are not "hard and fast" although the [3] Huntington disease 1 in 15,000 divisions between autosomal and X-linked types are (since Autosomal recessive the latter types are distinguished purely based on 1 in 625 the chromosomal location of Sickle cell anemia the gene). For example, (African Americans) achondroplasia is typically 1 in 2,000 considered a dominant Cystic fibrosis disorder, but children with two (Caucasians) genes for achondroplasia have a severe skeletal disorder that 1 in 3,000 Tay-Sachs disease achondroplasics could be (American Jews) viewed as carriers of. Sickle- cell anemia is also considered a Phenylketonuria 1 in 12,000 recessive condition, but heterozygous carriers have Mucopolysaccharidoses 1 in 25,000 increased immunity to malaria in early childhood, which could Glycogen storage diseases 1 in 50,000 be described as a related [citation needed] dominant condition. Galactosemia -
A Rare Case of Aicardi Syndrome
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Case Report Unlike the Textbook Triad: A Rare Case of Aicardi Syndrome Niharika Prasad1, Sanjay Purushothama2 1Senior Resident, Department of Radio-Diagnosis All India Institute of Medical Sciences, Patna 2Assistant Professor, Department of Radio-Diagnosis, Mysore Medical College and Research Institute, Mysore Corresponding Author: Niharika Prasad ABSTRACT Aicardi syndrome (AS) is an X-linked inherited disorder characterized by infantile spasms, chorioretinal lacunae, and agenesis or hypogenesis of the corpus callosum. Since the description of the first case of Aicardi syndrome in 1965 not many have contributed to the list, hence preserving its rarity. The purpose of this case report was to demonstrate the spectrum of MRI findings and follow up in the course of Aicardi syndrome. Key words: Corpus callosum; agenesis; Aicardi; microcephaly; infant INTRODUCTION limits and CSF testing did not yield any Aicardi syndrome (AS) was first clues to diagnosis. No chromosomal disease described by Jean Aicardi in 1965 and is pattern was discovered on analysis. Detailed characterized by agenesis or hypogenesis of birth and development history was elicited the corpus callosum, chorioretinal lacunae, from parents. No episode of seizures had and early infantile spasms. Most of AS occurred although they confirmed delayed patients develop normally until 3 months of milestones compared to a normal infant. age, and then, epileptic seizures and Plain MRI study of brain and orbits on a developmental delay start. It is an X-linked Siemens Magnetom Avanto 1.5T system dominant genetic disorder and lethal in revealed partial agenesis of corpus callosum males and, therefore, almost exclusively and unilateral optic nerve hypoplasia. -
Soonerstart Automatic Qualifying Syndromes and Conditions
SoonerStart Automatic Qualifying Syndromes and Conditions - Appendix O Abetalipoproteinemia Acanthocytosis (see Abetalipoproteinemia) Accutane, Fetal Effects of (see Fetal Retinoid Syndrome) Acidemia, 2-Oxoglutaric Acidemia, Glutaric I Acidemia, Isovaleric Acidemia, Methylmalonic Acidemia, Propionic Aciduria, 3-Methylglutaconic Type II Aciduria, Argininosuccinic Acoustic-Cervico-Oculo Syndrome (see Cervico-Oculo-Acoustic Syndrome) Acrocephalopolysyndactyly Type II Acrocephalosyndactyly Type I Acrodysostosis Acrofacial Dysostosis, Nager Type Adams-Oliver Syndrome (see Limb and Scalp Defects, Adams-Oliver Type) Adrenoleukodystrophy, Neonatal (see Cerebro-Hepato-Renal Syndrome) Aglossia Congenita (see Hypoglossia-Hypodactylia) Aicardi Syndrome AIDS Infection (see Fetal Acquired Immune Deficiency Syndrome) Alaninuria (see Pyruvate Dehydrogenase Deficiency) Albers-Schonberg Disease (see Osteopetrosis, Malignant Recessive) Albinism, Ocular (includes Autosomal Recessive Type) Albinism, Oculocutaneous, Brown Type (Type IV) Albinism, Oculocutaneous, Tyrosinase Negative (Type IA) Albinism, Oculocutaneous, Tyrosinase Positive (Type II) Albinism, Oculocutaneous, Yellow Mutant (Type IB) Albinism-Black Locks-Deafness Albright Hereditary Osteodystrophy (see Parathyroid Hormone Resistance) Alexander Disease Alopecia - Mental Retardation Alpers Disease Alpha 1,4 - Glucosidase Deficiency (see Glycogenosis, Type IIA) Alpha-L-Fucosidase Deficiency (see Fucosidosis) Alport Syndrome (see Nephritis-Deafness, Hereditary Type) Amaurosis (see Blindness) Amaurosis -
Holoprosencephaly and Strabismus
Holoprosencephaly and Strabismus Pavlina Kemp, MD, Grant Casey, Susannah Longmuir, MD June 11, 2012 Chief complaint Eye crossing History of Present Illness The patient is a 15 month-old female at presentation to the eye clinic, with history of severe hydrocephalus at birth. She was also diagnosed with alobar holoprosencephaly at birth with seizures. She was originally referred for eye crossing. We present her remarkable clinical course. Past Medical History: • Hydrocephalus s/p ventriculoperitoneal shunting • Holoprosencephaly (alobar type) • Seizure disorder Past Surgical History: • Ventriculoperitoneal shunt placement, 2004 • Ventriculoperitoneal shunt revision, 1/2005 • Ventriculoperitoneal shunt revision, 6/2005 Family History: No known family history of holoprosencephaly, amblyopia or strabismus. Social History: Patient lives at home with parents and two sisters. Medications: None Exam and Clinical Course: Age: 15 months Visual Acuity: Central, unsteady and maintained OD and central, unsteady and maintained OS Teller acuity testing: • Without correction OU: 20/800 Pupils: Equally round and briskly reactive, no relative afferent pupillary defect. Stereo Vision: Unable to test Motility and Strabismus: • Large variable esotropia • Bilateral elevation and abduction deficits • Intermittent horizontal nystagmus Cycloplegic Refraction: • OD: +4.00 • OS: +6.00 External Exam: Notable for large head circumference Slit Lamp Exam: Normal anterior segment exam OU without evidence of cataracts or other media opacities. Normal appearing optic nerves and normal dilated fundus examination. No sign of optic nerve hypoplasia in either eye. Figure 1: Axial and saggital MRI illustrating the enlargement of ventricles secondary to hydrocephalus. At this point, after discussion with her family, surgery for strabismus was deferred and correction of her hyperopia was attempted. -
PDF Download
Review Xatzipsalti Maria et al. Congenital Hypopituitarism: Various Genes, … Horm Metab Res 2018; 00: 00–00 Congenital Hypopituitarism: Various Genes, Various Phenotypes Authors Maria Xatzipsalti1, 2, Antonis Voutetakis1, Lela Stamoyannou2, George P. Chrousos1, Christina Kanaka-Gantenbein1 Affiliations ABSTRacT 1 Division of Endocrinology, Diabetes and Metabolism, The ontogenesis and development of the pituitary gland is a First Department of Pediatrics, Medical School, National highly complex process that depends on a cascade of transcrip- and Kapodistrian University of Athens, “Aghia Sofia” tion factors and signaling molecules. Spontaneous mutations Children's Hospital, Athens, Greece and transgenic murine models have demonstrated a role for 2 First Department of Pediatrics, “Aglaia Kyriakou” many of these factors, including HESX1, PROP1, PIT1, LHX3, Children's Hospital, Athens, Greece LHX4, SOX2, SOX3, OTX2, PAX6, FGFR1, SHH, GLI2, and FGF8 in the etiology of congenital hypopituitarism. Genetic muta- Key words tions in any of these factors can lead to congenital hypopitui- pituitary, combined pituitary hormone deficiency, congenital tarism, which is characterized by the deficiency in one or more hypopituitarism, transcription factors, syndromic hypopitui- pituitary hormones. The phenotype can be highly variable, tarism, non-syndromic hypopituitarism consisting of isolated hypopituitarism or more complex disor- ders. The same phenotype can be attributed to different gene received 27.03.2018 mutations; while a given gene mutation can -
Engineering Region-Specific Brain Organoids from Human Stem Cells to Study Neural Development and Disease
CHAPTER TWELVE Building the brain from scratch: Engineering region-specific brain organoids from human stem cells to study neural development and disease Fadi Jacoba,b,c, Jordan G. Schnolla, Hongjun Songa,d,e,f, and Guo-li Minga,d,e,g,* aDepartment of Neuroscience and Mahoney Institute for Neurosciences, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States bThe Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, United States cMedical Scientist Training Program, Johns Hopkins University School of Medicine, Baltimore, MD, United States dDepartment of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States eInstitute for Regenerative Medicine, University of Pennsylvania, Philadelphia, PA, United States fThe Epigenetics Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States gDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States *Corresponding author: e-mail address: [email protected] Contents 1. Introduction 478 1.1 Fundamentals of mammalian brain development 479 1.2 Human-specific features 482 1.3 Comparison of in vitro human cell models 482 2. Generation of region-specific brain organoids from human stem cells 484 2.1 Unguided differentiation: Cerebral organoids 484 2.2 Guided differentiation: Region-specific brain organoids 489 3. Advancements in cellular complexity of brain organoids 496 3.1 Fusion of region-specific brain organoids 497 3.2 Enhancing glial cell production and maturation 499 3.3 Reconstitution of resident immune cells and vasculature 500 3.4 Technical modifications for long-term culture 501 3.5 In vivo orthotopic xenotransplantation 503 4. -
Case Report: Aicardi Syndrome Presenting As Cleft Lip and Palate
Case Report Open Access J Neurol Neurosurg Volume 3 Issue 5 - May 2017 DOI: 10.19080/OAJNN.2017.03.555625 Copyright © All rights are reserved by Juan Pablo Appendino Case Report: Aicardi Syndrome presenting as Cleft Lip and Palate Danielle Weidman1 and Juan Pablo Appendino2* 1Paediatric Resident, The Hospital for Sick Children, University of Toronto, Canada 2Department of Pediatrics, University of Calgary, Canada Submission: March 02, 2017; Published: May 30, 2017 *Corresponding author: Juan Pablo Appendino, Clinical Associate Professor, Department of Paediatrics, Cumming School of Medicine, University of Calgary, Pediatric Epilepsy and Child Neurology, Alberta Children’s Hospital 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Tel: Fax: 403-955-7609; Pager: 403-212-8223 #14691; Email: Abstract Aicardi syndrome (AS) is an unusual neurological disorder that was originally described in 1965 by Dr. Jean Aicardi. This disorder is characterized by a triad of abnormalities: agenesis of the corpus callosum, chorio retinal lacunae, and infantile spasms. There are infrequent reports of cleft lip and palate in patients with AS. This report details a case of a patient with AS who presented with left-sided cleft lip and palate and right eye coloboma to her pediatrician; however, the diagnosis of AS was not suspected until later when the she presented with appropriateInfantile Spasms. diagnosis. The discussion will focus on the existing literature of AS with cleft lip and palate and ophthalmological findings offering a learning point to the pediatric community in regards with her clinical, neuroimaging and neurophysiological findings for an earlier and Introduction Aicardi syndrome (AS) is a relatively rare disease that was presents to the pediatrician for medical advice. -
Prenatal Diagnosis of Congenital Fetal Malformations Medically Terminated: a Retrospective Analysis
DOI - 10.21276/obgyn.2021.8.1.13 ISSN Print – 2454-2334; ISSN Online – 2454-2342 RESEARCH ARTICLE Prenatal diagnosis of congenital fetal malformations medically terminated: a retrospective analysis Papa Dasari, Pratima Aggrawal Corresponding author: Dr. Papa Dasari, Professor, Department of Obstetrics and Gynaecology, JIPMER, Puducherry, India; Email: [email protected] Distributed under Attribution-Non Commercial – Share Alike 4.0 International (CC BY-NC-SA 4.0) ABSTRACT Objectives: The primary objective of this study is to find out demographic and clinical profile of women with congenital malformation who underwent MTP and secondary objective is to find out types of congenital malformations, risk factors and method of termination of pregnancy. Methods: This retrospective cohort involved women with congenital malformations who underwent medical termination (MTP) over a 3 year period (July 2016 to June 2019) in a tertiary care facility. Data was analysed with respect to gestational age and spectrum of malformations and results were expressed as frequencies and proportions. Results: Of the 640 women underwent MTP, 245 were for congenital fetal malformations (38.2%). The mean age was 25 years, 95% belonged to low socioeconomic status and from rural background and were Hindus. The most common system affected was CNS (55.5%) followed by renal. The most common lethal anomalies were anencepahaly and hydrocephalous. Majority were diagnosed between 16 to 20 weeks and only 3 % were diagnosed in first trimester. Risk factors were third and second degree consanguinity (27%), diabetes in pregnancy (28%) and non consumption of folic acid preconceptionally (92%). Conclusion: The most common anomalies are largely preventable as they involved CNS and 40% were anencephaly. -
The Genetics of Rett Syndrome
TheThe GeneticsGenetics ofof RettRett SyndromeSyndrome JohnJohn ChristodoulouChristodoulou Head, NSW Rett Syndrome Research Unit Western Sydney Genetics Program, Children’s Hospital at Westmead Discipline of Paediatrics & Child Health, University of Sydney ClinicalClinical DiagnosisDiagnosis •• specificspecific developmentaldevelopmental profileprofile basedbased onon aa consistentconsistent constellationconstellation ofof clinicalclinical featuresfeatures •• diagnosticdiagnostic criteriacriteria developeddeveloped •• classicalclassical andand variantvariant RTTRTT phenotypesphenotypes – atypical Rett syndrome – “speech preserved” variant – congenital onset variant – male Rett syndrome equivalent GeneticsGenetics ofof RettRett SyndromeSyndrome X:X: autosomeautosome translocations:translocations: - t (X; 22) - Xp11.22 - t (X; 3) - Xp21.3 Deletions:Deletions: - del (3) (3p25.1 - p25.2) - del (13) (13q12.1 - q21.2) mtDNAmtDNA mutationmutation screening:screening: - 16S rRNA - A2706G (1 patient & mother) ExclusionExclusion mappingmapping inin familialfamilial cases:cases: (incl. Brazilian family with 3 affected sisters) - gene likely to be in Xq28 or Xpter “Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG binding protein 2” (Amir et al, Nature Genet 1999: 23; 185 - 188) 6 mutations identified in 21 sporadic classical cases - 4 de novo missense mutations in methyl-binding domain (MBD) - 1 de novo frame-shift mutation in transcription repression domain (TRD) - 1 de novo nonsense mutation in TRD MECP2MECP2 MutationsMutations